长期核苷(酸)类似物治疗的白色人种乙肝肝硬化患者中肝细胞癌的临床特征与结局
研究2005至2016年接受长期核苷(酸)类似物治疗且处于监测中的乙肝肝硬化患者新发肝细胞癌的临床特征与结局,排除治疗前6个月内发生者。共纳入76例,中位年龄67岁,84%为男性,96%为白色人种,92%为代偿期肝硬化。肝细胞癌多为单发(78%)、中位直径20 mm、92%为早期,78%接受了潜在根治性治疗,完全缓解61例(80%),5年肝脏相关生存率74%。
要点
- 长期核苷(酸)类似物治疗的乙肝肝硬化患者仍可发生肝细胞癌,多为单发、小肿瘤且处于早期。
- 92%的肝细胞癌为早期,78%接受了潜在根治性治疗(消融39%、手术切除28%、肝移植11%)。
- 完全缓解61例(80%),中位复发时间20.2个月,5年肝脏相关生存率74%。
核心结论
- 长期核苷(酸)类似物治疗期间发生的肝细胞癌为单发、小肿瘤,适合根治性治疗,可获得极佳的5年生存率。
研究设计与样本
- 研究纳入2005年至2016年间在监测中接受核苷(酸)类似物治疗的乙肝病毒感染者中新发肝细胞癌的病例,排除治疗最初6个月内发生者,共76例。
- 研究中位年龄67(40-83)岁,84%为男性,96%为白色人种,95%为HBeAg阴性,96%HBV DNA检测不到,83%丙氨酸氨基转移酶水平正常,92%为代偿期肝硬化。
主要发现
- 中位血清甲胎蛋白水平为4(1-3615)ng/mL,36%的患者甲胎蛋白>7 ng/mL。
- 肝细胞癌单发者占78%,中位直径20(6-57)mm,92%处于早期,78%接受了潜在根治性治疗(39%消融、28%手术切除、11%肝移植)。
- 总体完全缓解61例(80%):40例经一线治疗后、3例经二线治疗后、2例经三线治疗后,另有16例接受肝移植(其中8例为二线治疗)。
- 肝细胞癌诊断后随访45(7-144)个月,19例死亡,其中84%死于肝细胞癌进展。
- 中位复发时间20.2(3-53)个月,累积5年肝脏相关生存率为74%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long-term oral nucleos(t)ide analogue (NUC) therapy in hepatitis B virus (HBV)-related compensated cirrhotics prevents clinical decompensation but not hepatocellular carcinoma (HCC) development. AIMS: To define the clinical features and outcomes of HCC in long-term NUC-treated HBV patients. METHODS: All HCCs developing between 2005 and 2016 in NUC-treated HBV patients under surveillance were studied, excluding those that occurred within the first 6 months of therapy. Clinical features of HCC, alpha faetoprotein (AFP) patterns and patients' outcome were studied. RESULTS: Seventy-six HCC patients were included. Median age was 67 (40-83) years, 84% males, 96% Caucasian, 95% HBeAg-negative, 96% with undetectable HBV DNA, 83% with normal ALT levels, and 92% with compensated cirrhosis. Median serum AFP levels were 4 (1-3615) ng/mL (>7 ng/mL in 36%). HCC was monofocal in 78%, had a median diameter of 20 (6-57) mm and was in its early stage in 92% which allowed potentially curative treatments in 78% (39% ablation, 28% surgical resection, 11% liver transplantation). Overall, a complete response was obtained in 61 (80%) patients: in 40 after a first-line treatment, in 3 after the second-line treatment, in 2 after the third-line treatment, while 16 underwent liver transplantation (8 as second line). During 45 (7-144) months after HCC diagnosis, 19 patients died, 84% from HCC progression. The median time to recurrence was 20.2 (3-53) months, and the cumulative 5-year liver-related survival was 74%. CONCLUSIONS: HCCs developing in patients under long-term NUC treatment were single, small tumours, amenable to curative therapies able to confer excellent 5-year survival rates.
引用
- Loglio A, Iavarone M, Grossi G, et al. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. Aliment Pharmacol Ther. 2018. PMID: 29920698. doi:10.1111/apt.14848
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。